Analysts expect the South-San Francisco-based company to report $30.2 million in revenues for Q4 and $116.4 million in full-year 2019 revenues.
A missense change in a gene coding for an androgen production enzyme had apparent ties to poor lung function and reduced glucocorticoid drug response.
Horizon also said it will provide access to the technology to business partners for the development of more effective multi-gene knockout cell therapy programs.
Under the agreement, the companies plan to make Swift's library preparation kits compatible with MGI's DNBSEQ sequencers.
Using corrected TMB and other variables allowed Johns Hopkins researchers to more accurately predict response to immune checkpoint blockade in lung cancer.
The Beverly, Massachusetts-based company plans to use the funding to expand its PlexWell sequencing library prep technology into new areas.
The company said it plans to use the platform for research and development of companion diagnostics and in other oncology and precision medicine applications.
The Mayo Clinic Platform, now headed by John Halamka, will lean on Nference for multi-omics analytics to inform biomedical R&D and postmarketing surveillance.
The companies will develop tissue-based companion diagnostics for Amgen's investigational treatment AMG 510 for non-small cell lung cancer.
On Monday Qiagen reiterated its preliminary 2019 earnings figures and addressed an investor's wrath, while Guardant Health highlighted its cancer testing plans.
The study, led by NYU researchers, provides a mathematical framework to find gene sets identifiable via both methods, revealing tissue architecture.
Illumina also said it is developing a regulated version of its high-throughput NovaSeq system to address growing demand for a diagnostic platform with higher throughput.
The clearances pave the way to clinical applications for three of MGI's instruments but the BGI subsidiary faces legal challenges from Illumina in Europe and the US.
Illumina will grant Roche rights to develop and distribute IVD tests on its Dx sequencing instruments, while Roche will help expand the CDx claims for Illumina's solid tumor panel.
The firms have agreed to develop infectious disease and women's heath testing assays using SpeeDx's proprietary technology.
The deal gives Definitive Healthcare a foothold in the genomics market as it looks to build its own genomic data pipeline to serve through PatientFinder's CohortBuilder tool.
Daiichi Sankyo plans to use the ERS IP to support its own R&D initiatives to address areas of unmet medical need, the company said.
In December, the companies agreed to develop CRISPR tools with the aim of generating new engineered cell lines for the biopharmaceutical industry.
The Korean company said it plans to use equipment and reagents from Thermo Fisher and to expand its overseas markets for CE sequencing services.
With a large set of data collected over time, Stanford researchers detected molecular markers for aging but saw considerable variation in "ageotypes."
The Washington Post reports that a Russian Academy of Sciences commission has led to the retraction of hundreds of scientific papers.
News 4 Jax reports that a Florida bill to prevent life and long-term care insurers from using genetic information in their coverage decisions has easily passed one committee.
The Los Angeles Times' Daily Pilot reports the chief executive of Vantari Genetics has pleaded guilty in a kickback scheme.
In Science this week: potentially pathogenic mutations found in hematopoietic stem cells from young healthy donors, and more.